Journal
ANNALS OF ONCOLOGY
Volume 23, Issue -, Pages 92-97Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mds310
Keywords
immunotoxins; lymphomas; monoclonal antibodies; small molecules
Categories
Ask authors/readers for more resources
Despite improvements in the diagnosis and management of lymphomas, many patients remain incurable with available treatments. Advances in preclinical research and a better understanding of the molecular biology of lymphomas have allowed the development of a high number of therapeutic agents with innovative mechanisms of action. Many of these new agents have shown activity in patients not responding to standard treatments and there is optimism that their incorporation into the standard of care can result in improved treatment outcomes. Here we review new monoclonal antibodies and small molecules that have recently entered clinical evaluation for patients with lymphomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available